드림씨아이에스 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 양태식, was filed 26 Jun 2026.
드림씨아이에스: what insiders have been doing
This page follows insider dealings at 드림씨아이에스 as filed with DART (FSS), a company from the Health Care sector. Over the twelve months to 2 November 2026, 13 filings were filed, from 11 insiders.
Only purchases show up on the open market, 12 purchases in all worth €34k, filed by 10 insiders. The totals exclude 11 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 9 senior executives and 1 chief executive. Biggest ticket of the year: €34k, bought by 유정희 and made public on 6 April 2026 (0.078% of market cap).
With 13 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Our records for 드림씨아이에스 go back to 2021, with 42 purchases and no sales on the open market in total.
The last purchase on record was published on 26 June 2026, which is 137 days ago. Typically, a trade is published a median of 5 days after it takes place. Until a filing is published, the market cannot know about the trade.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySale+4 other insiders
Since the insiders bought
- -12.7%Entry ₩4,570 · Close 30 Oct 2026 ₩3,990
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 3,000 sharesShareKRXDART:20260626000424Canonical exit: 24 Sept 2026 (T+90)
- 5,000 sharesShareKRXDART:20260626000390Canonical exit: 24 Sept 2026 (T+90)
- 1,975 sharesShareKRXDART:20260527000013Canonical exit: 20 Aug 2026 (T+90)
- 2,000 sharesShareKRXDART:20260527000016Canonical exit: 20 Aug 2026 (T+90)
- 26,400 sharesShareKRXDART:20260526000191Canonical exit: 24 Aug 2026 (T+90)
- 12,000 shares@ ₩4,870.66670.078% mcap100.0% of flowShareKRXDART:20260406002995Canonical exit: 29 Jun 2026 (T+90)
- 12,048 sharesShareKRXDART:20260120000072Canonical exit: 20 Apr 2026 (T+90)
- 60,000 sharesShareKRXDART:20260120000058Canonical exit: 20 Apr 2026 (T+90)
- 7,968 sharesShareKRXDART:20260120000091Canonical exit: 20 Apr 2026 (T+90)
- 5,000 sharesShareKRXDART:20260120000097Canonical exit: 20 Apr 2026 (T+90)
- 16,000 sharesShareKRXDART:20260120000065Canonical exit: 20 Apr 2026 (T+90)
- 11,200 sharesShareKRXDART:20260120000115Canonical exit: 20 Apr 2026 (T+90)
- ●Executives0DART
- 30,000 sharesShareKRXDART:20241216000320Canonical exit: 16 Mar 2025 (T+90)
- ShareKRXDART:20231207000136Canonical exit: 29 Feb 2024 (T+90)
- ShareKRXDART:20231129000514Canonical exit: 20 Feb 2024 (T+90)
- ShareKRXDART:20231018000018Canonical exit: 9 Jan 2024 (T+90)
- ShareKRXDART:20231017000303Canonical exit: 9 Jan 2024 (T+90)
- ShareKRXDART:20231017000287Canonical exit: 9 Jan 2024 (T+90)
- ShareKRXDART:20231017000312Canonical exit: 9 Jan 2024 (T+90)
- ShareKRXDART:20231017000309Canonical exit: 9 Jan 2024 (T+90)
- ShareKRXDART:20231017000264Canonical exit: 9 Jan 2024 (T+90)
- 1,590,028 sharesKRXDART:20231017000253Canonical exit: 9 Jan 2024 (T+90)
- ShareKRXDART:20231017000274Canonical exit: 9 Jan 2024 (T+90)
- ShareKRXDART:20231017000296Canonical exit: 9 Jan 2024 (T+90)
25 of 43 declarations
About 드림씨아이에스
드림씨아이에스 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development and commercialization of innovative solutions in the health field.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
